GlaxoSmithKline Pharmaceuticals reported a 5.70% increase in consolidated net profit to ₹277.86 crore for the quarter ended March 2026, compared to ₹262.87 crore in the corresponding quarter of the previous year. According to the latest financial results, the company's total income rose 1.60% to ₹1,031.25 crore during the quarter, up from ₹1,015.05 crore in Q4 FY2025. The operating profit margin (OPM) improved to 35.26% in the current quarter from 34.20% in the year-ago period. Earnings per share (EPS) increased to ₹16.40 for the quarter compared to ₹15.52 in Q4 FY2025, representing a 5.67% growth.
For the complete financial year 2025-26, the pharmaceutical company demonstrated stronger growth momentum with net profit rising 11.69% to ₹1,035.98 crore compared to ₹927.58 crore in the previous financial year. As reported by the latest financial data, total income for FY2026 grew 1.85% to ₹3,967.03 crore from ₹3,895.14 crore in FY2025. The company's profit before tax (PBT) increased 10% to ₹1,385.39 crore for the full year, while PBDT grew 10% to ₹1,451.83 crore. Earnings per share for the full year increased 11.67% to ₹61.15 from ₹54.76 in the previous year.
The company's Q4 FY2026 performance showed some sequential decline compared to the previous quarter. According to the latest quarterly comparison, total income decreased 3.92% to ₹1,031.25 crore from ₹1,073.38 crore in Q3 FY2026. Net profit also declined 6.01% to ₹277.86 crore from ₹295.62 crore in the previous quarter. Earnings per share for Q4 FY2026 was ₹16.40 compared to ₹17.45 in Q3 FY2026, reflecting a 6.02% sequential decline.
Shares of GlaxoSmithKline Pharmaceuticals Limited were trading at ₹2,406.85 on BSE as of the latest trading session, compared to the previous close of ₹2,448.10. The stock witnessed significant trading activity with 10,967 shares traded across 1,022 trades during the day. The stock hit an intraday high of ₹2,493.00 and an intraday low of ₹2,386.35, with the net turnover reaching ₹267.81 lakh. The trading activity reflects investor interest in the company's consistent profit growth and operational efficiency demonstrated across both quarterly and annual periods.
